A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
192actual
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-03 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-13 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderately to Severely Active Rheumatoid Arthritis
Interventions
- Biological: CT-P13 SC Auto-Injector
- Biological: Placebo Auto-Injector
Primary outcome
what the primary-completion date above is the date OFProportion of patients achieving clinical response according to the ACR20 criteria at Week 12
measured Week 0 ~ Week 12
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed